Tower Research Capital LLC (Trc) Salarius Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.17 - $0.25 $9,370 - $13,780	-55,123 Reduced 69.59%	24,089 $5,000
Q2 2022 Aug 15, 2022	BUY	$0.16 - $0.42 $10,762 - $28,250	67,264 Added 562.97%	79,212 $17,000
Q1 2022 May 12, 2022	BUY	$0.34 - $0.54 $2,441 - $3,877	7,181 Added 150.64%	11,948 $5,000
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.01 $1,942 - $4,003	3,964 Added 493.65%	4,767 $2,000
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.15 $534 - $768	668 Added 494.81%	803 $1,000

Q2 2021 Aug 16, 2021	SELL	$1.02 - $1.52 $59,858 - $89,201	-58,685 Reduced 99.77%	135 $0
Q1 2021 May 17, 2021	BUY	$1.0 - $3.0 $50,436 - $151,308	50,436 Added 601.57%	58,820 $87,000
Q4 2020 Feb 16, 2021	SELL	$0.65 - $1.34 $28,752 - $59,274	-44,235 Reduced 84.07%	8,384 $8,000
Q3 2020 Nov 16, 2020	BUY	$0.77 - $1.52 $40,516 - $79,980	52,619 New	52,619 $44,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.1M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.